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ABSTRACT
Objective: To evaluate the impact of value-based beneﬁt design (VBBD)
on adherence to diabetes medications.
Methods: Health Alliance Medical Plans piloted VBBD for diabetes medi-
cations for a subgroup of 5400 enrollees in January 2007 while keeping
drug beneﬁts unchanged for the remaining plan enrollees. A difference in
difference method (DID) was used to evaluate the effect of VBBD based on
pharmacy claim data. Patients with unchanged beneﬁts in the same plan
were used as the control group. Adherence was measured by the propor-
tion of days covered. Propensity score weighting was used to balance
characteristics of the case group and the control group.
Results: There were 71 patients in the case group and 5037 patients in the
control group. The patients in the two groups had comparable character-
istics after propensity score weighting. After the implementation of VBBD,
the average copayment per 30 days of supply for diabetes medications
decreased from $15.3 to $10.1 for the case group and increased from
$14.6 to $15.1 for the control group. The probability of being adherent
increased from 75.3% to 82.6% for the case group and was roughly
unchanged from 79.1% to 78.5% for the control group. Propensity score-
weighted DID analysis showed that patients with copayment reduction
had greater odds of being adherent: odds ratio = 1.56, P = 0.03, 95%
conﬁdence interval 1.04–2.34.
Conclusion: A VBBD program that reduced the copayment for diabetes
medications by 36.1% reduced the number of nonadherent patients by
30.0%.
Keywords: adherence, compliance, diabetes, difference in difference
method, propensity score, value-based beneﬁt design.
Introduction
Value-based beneﬁt design (VBBD) is a new health beneﬁt design
that bases medication copayment on clinical value instead of
acquisition costs [1,2]. The rationale behind VBBD is that many
valuable treatments for chronic illnesses, such as diabetes medi-
cations, are often used suboptimally, potentially leading to unde-
sirable outcomes such as an increase in complications and
avoidable hospitalizations [3]. An important barrier for the sub-
optimal consumption of these medications is copayment [4,5].
Traditional beneﬁt designs determine copayment based on acqui-
sition cost and can result in copayment high enough to reduce
compliance. Preliminary evidence suggests that the use of both
high and low value health-care services are reduced as copayment
increases [1].
VBBD provides a new approach to managing chronic illnesses
based on the argument that quality improvement and cost con-
tainment are two sides of the same coin [6]. VBBD advocates
better alignment between copayment and clinical value: copay-
ment should be reduced to improve clinical outcomes for high-
value therapy. In the long run, the improved clinical outcomes
may translate into cost savings. Simulation studies show that
VBBD can lead to substantial reduction in hospitalization events,
disabilities, absenteeism, presenteeism, and overall medical care
costs [7,8].
Implementation of VBBD has demonstrated promising
results. The most prominent example of VBBD is the experience
of Pitney Bowes, a large employerwith a self-insuredmedical plan.
It had a traditional three-tier drug beneﬁt plan with 10%/30%/
50% coinsurance in 2001. In 2002, Pitney Bowes moved all
diabetes, asthma, and hypertension medications into tier 1 with
10% coinsurance. Two years after implementation of this
program, the number of nonadherent diabetes patients fell by
two-thirds, and total costs of treating diabetes patients were
reduced by 6% [9]. A second article by Chernew et al. evaluated a
VBBDprogram under a diseasemanagement program. The VBBD
program moved ﬁve classes of medications from a three-tier of
$5/$25/$45 to a three-tier of $0/$12.50/$22.50. Using another
employer with the same disease management program as the
control group, this research showed that the VBBD program
improvedmedication possession ratios (MPRs) for diabetes drugs,
statins, angiotensin-converting enzyme inhibitors/angiotensin
receptor blocker, and beta-blockers by 4.02, 3.39, 2.59, and 3.02
percentage points, respectively [10]. These early successful stories
motivated many health plans to implement VBBD programs [11].
Skepticism toward the effectiveness of VBBD also has grown
as more health plans implement VBBD. Critics point out that
there is scant evidence to support the effectiveness of VBBD
[11,12]. The two cases of VBBD that have been published have
methodological concerns. The Pitney Bowes research should be
considered descriptive because no control population is available
[9]. In addition, it is difﬁcult to isolate the effect of VBBD from
the effects of disease management initiatives that were imple-
mented simultaneously. The research by Chernew et al. used a
difference in difference (DID) approach with a control group, but
little information was provided regarding whether the case and
the control groups were comparable [10].
More research on the outcomes associated with VBBD is
urgently needed. The policy implications are profound: VBBD
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could fundamentally change the landscape of chronic care if it is
proven to be effective in improving quality of care and reducing
costs. Serious discussions are under way to broaden the use of
VBBD. Legislation has been introduced to allow Medicare to test
the concept of VBBD [13]. The recently passed health-care
reform bill contains language to allow the Department of Health
and Human Services to develop guidelines for health plans to
adopt VBBD [14].
This research contributes to the discussion by evaluating the
impact of VBBD on adherence to diabetes medications in Health
Alliance Medical Plans (HAI). The impact of VBBD on adherence
to diabetes medication was assessed by using a DID approach.
Propensity score weighting was used within DID to make the
patients in the case group and the control group to have similar
characteristics.
Methods
Intervention
HAI is a large health plan in Illinois with over 250,000 enrollees.
In 2006, its drug beneﬁt for commercial managed care enrollees
charged $10 copayment for generic drugs, 30% copayment for
preferred brand drugs, and 50% copayment for nonpreferred
brand drugs. Starting January 1, 2007, HAI implemented VBBD
for Carle Clinic (HAI’s owner) with a total of 5400 enrollees
including employees and dependents. All enrollees and providers
were contacted by mail with a description of the new program.
The VBBD program placed a comprehensive list of diabetes
medications (Appendix 1 found at: http://www.ispor.org/
Publications/value/ViHsupplementary/ViH13i6_Zeng.asp) into
tier 1 with a ﬂat copayment of $10. HAI moved most diabetes
medications and supplies in tier 2 (preferred brand) and a few in
tier 3 (nonpreferred brand) into the VBBD program. All major
diabetes medication classes were included in the program. No
new disease management initiative was rolled out along with the
VBBD program. The drug beneﬁt for the rest of the plan enrollees
remained unchanged.
Data and Sample Selection
The data used in the research came from MedImpact Healthcare
Systems, Inc., HAI’s pharmacy beneﬁts management company.
The MedImpact data set contained pharmacy claims and eligi-
bility data but did not contain medical claims related to ambu-
latory and inpatient care. To be included in the study, all patients
needed to be continuously enrolled in HAI from January 1, 2005
to December 31, 2007. The case group included members in the
Carle Clinic plan who implemented the VBBD while the control
group included all other members in HAI’s commercial managed
care segment. Enrollment in 2005 was necessary to capture the
medication use history 12 months before the baseline period.
Patients also needed to have at least one diabetes medication
claim in each of the three years. This requirement was to ensure
that patients in the sample used diabetes medications before
2006 so that all patients had one year to measure baseline adher-
ence level. It also reduced the likelihood that the sample con-
tained members who were being treated for gestational diabetes.
The ﬁnal data set contained 71 patients in the case group and
5037 patients in the control group. Each patient had two obser-
vations in the ﬁnal data set, one in 2006 and the other in 2007.
Figure 1 illustrates the data construction process.
Outcome Variable
The outcome variable measured was adherence to diabetes medi-
cations. Adherence to diabetes medications is critical to successful
treatment of diabetes. Consequences of poor adherence include
inadequate HbA1C control [15–17], subsequent clinical inertia in
advancing to insulin treatment [18], higher medical costs, and
higher mortality rate [3,19–23]. In this research, adherence to
diabetes medication was measured by the proportion of days
covered (PDC), deﬁned as number of days covered by at least one
diabetes medication in a year divided by 365 days [19,20]. To
calculate PDC, every day of the 365 days was ﬂagged as either 0 or
1 to indicate whether the day was covered by at least one diabetes
medication based on ﬁll date and days of supply. Overlapping
prescriptions within the same diabetes medication subclass (met-
Figure 1 Data construction process.
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formin, sulfonylureas, thiazolidinediones, incretin mimetics,
DPP-4 inhibitors, and insulin) were linked so that the ﬁll date of
the second prescription claim followed the end date of the ﬁrst
prescription claim. Prescriptions extending beyond the 365 day
monitoring period were truncated. The maximum value of PDC is
1 and the minimum value is 0. A threshold of 80% was used to
classify patients as either adherent or nonadherent [15,20–23].
Propensity ScoreWeighted DID
A DID approach was used to evaluate the effects of VBBD on
adherence to diabetes medications. Under the DID approach,
diabetes patients in the subgroup that had implemented VBBD
were set as the case group (G = 1), while the rest of the diabetes
patients in the same health plan were set as the control group
(G = 0). Adherence to diabetes medications was observed for all
the patients one year before implementation of VBBD (T = 0)
and one year after implementation of VBBD (T = 1). The treat-
ment effect b is the difference between the case group and the
control group one year after VBBD, adjusting for the difference
between the two groups one year before VBBD:
β = = =( ) − = =( ) − = =( )( −
= =( ))
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E Y G T
1 1 0 1 1 0
0 0
, , ,
, . (equation 1)
By using a group ﬁxed effect and a time period ﬁxed effect,
DID assumes that the gap between the case group and the control
group in the follow-up period would have been unchanged had
VBBD not been implemented. This assumption requires both the
case group and the control group to change over time at the same
pace. When this assumption is violated, a DID estimate of the
VBBD effect could be problematic. For example, suppose that the
relationship between age and adherence was a curve: adherence
may initially increase as patients become older but decrease after
a certain stage. If the case group had a younger population and
the control group had an older population, researchers could
observe increased adherence in the case group and decreased
adherence in the control group after VBBD even when VBBD did
not have any impact on adherence to medications.
Ideally, the case group and the control group need to have
similar characteristics to allow for a valid comparison. This
research used propensity scores to create a control group with
balanced covariates with the case group. A propensity score is the
probability of being in the case group given all observable cova-
riates [24]. It can balance the conditional distribution of covari-
ates given a certain propensity score for the case and the control
group. By using propensity scores, this research was able to create
a “quasi-randomized” experiment in that two patients were
similar except for their case and control assignment status [25].
Usually, a logistic model is used to predict the probability of
being in the case group. In this research, a simple logistic model
could be problematic because the case and the control groups
were unbalanced. The number of patients in the control group
was almost 71 times the number of patients in the case group.
Research has shown that a logistic model can underestimate the
probability of rare events [26,27]. It is recommended that the
probability of being in the case group should not be lower than
0.1 in a propensity score model [26].
To generate an accurate propensity score, we ﬁrst drew a
random sample from the control group to lower the number of
patients in the control group to be 639, 9 times of the number of
patients in the case group. The goal was to increase the prob-
ability of being in the case group to 0.1. Then we conducted a
logistic regression to predict the probability of being in the case
group. Covariates for the logistic regression included age, sex,
average copayment for diabetes medications, average days of
supply for diabetes medications, whether patients used insulin or
not in 2005, and comorbidities in 2005. Comorbidities in this
research were deﬁned using RxRisk categories [28]. A series of
dummy variables were used to approximate whether patients had
various diseases such as hypertension and dyslipidemia. Only
comorbidities that inﬂuenced over 10% of patients were included
in the logistic regression.
A propensity score weighting method was used to balance the
characteristics of the case and the sample control group [29–31].
Compared with propensity score matching and stratiﬁcation,
propensity score weighting was attractive because it was robust to
the misspeciﬁcation of the regression model. Simulation showed
that it was able to lead to an unbiased estimate of the average
treatment effect even when the model was not correctly speciﬁed
[31]. Under the propensity score weighting method, each patient
was assigned a propensity score weight based on propensity score.
For patients in the case group, the weight was equal to the inverse
of the propensity score. For patients in the control group, the
weight was equal to the inverse of 1-propensity score [29–31]. The
weighted case group and the weighted control group should have
similar baseline characteristics. Aweighted logistic model was run
to estimate the impacts of VBBD on adherence to diabetes medi-
cations. SAS 9.1 (SAS Institute, Cary, NC) was used to perform all
statistical analyses in this research.
Results
Descriptive Characteristics
Table 1 provides the baseline descriptive statistics for the case
group and the selected sample control group before and after
being weighted by propensity scores. A t-test was performed to
test whether the patients in the case and the control group were
statistically different. Before propensity score weighting, the
patients in the case and the control group were different in
several ways. Compared with the patients in the control group,
the patients in the case group were younger (58.2 vs. 51.1,
P < 0.001) and more likely to use insulin in 2005 (40.8% vs.
27.7%, P = 0.02). The patients in the two groups were also
different in the prevalence rates of coronary/peripheral vascular
diseases (P = 0.01) and heart disease/hypertension (P < 0.001).
After each patient was weighted by propensity score weights,
only the prevalence rates of coronary/peripheral vascular diseases
(P < 0.001) and cystic ﬁbrosis (P = 0.03) were statistically differ-
ent across the two groups. All other variables including age,
propensity scores, and insulin use were not statistically different
across the two groups. The similar propensity scores for the
patients in the two groups suggested that after weighting,
patients in either group had equal propensity of being in the case
group. This helped create a process in which the patients in the
two groups were similar except their group assignment.
Table 2 compares copayment and days of supply before and
after VBBD. It shows that on average, the patients in the case
group had higher copayment per claim ($22.4, SD = 14.8) than
the patients in the control group ($16.7, SD = 10.2, P < 0.001) in
2006. Part of the difference can be attributed to the fact that the
patients in the case group had longer days of supply (39.5,
SD = 19.2) than the patients in the control group (36.9,
SD = 17.8, P = 0.26). After adjustments for days of supply, the
average copayment per 30 days of supply for the case group was
$18.8 (SD = 14.5), signiﬁcantly higher than the average copay-
ment per 30 days of supply for the control group ($14.3,
SD = 8.0, P < 0.001). After propensity score weighting, the dif-
ferences in baseline copayment, days of supply, and copayment
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per 30 days of supply vanished. None of the differences were
statistically signiﬁcant.
Propensity score weighting also reduced the gap of adherence
level between the two groups substantially. Before VBBD, the
patients in the case group had lower adherence rate (PDC  0.8)
compared with the patients in the control group (69.0% vs.
79.3%, P = 0.05). The difference was diminished to less than
four percentage points after propensity score adjustment (75.3%
vs. 79.1%, P = 0.23). The distribution of PDC value for both
groups was highly skewed with a heavy concentration of
PDC = 1. Both weighted case and weighted control group had
mean PDC equal to 0.88 before VBBD.
After VBBD, the average days of supply per claim increased
for both the case and the control group. The average days of
supply for the weighted case group increased from 36.4
(SD = 51.7) in 2006 to 44.4 (SD = 74.4) in 2007, and from 37.2
(SD = 19.1) to 41.9 (SD = 23.8) for the weighted control group.
The simultaneous increase in days of supply reﬂected HAI’s
efforts in promoting longer days of supply of medications for
patients with chronic illnesses, independent of the VBBD
program. Having a control group within the same health plan
was critical to control common changes happened within a plan.
The VBBD program had substantial impacts on the patients’
copayment. After VBBD, the weighted mean copayment per 30
days of diabetes medications supply decreased from $15.3 to
$10.1 for the case group. At the same time, the copayment per 30
days of supply remained largely unchanged for the control group:
from $14.6 in 2006 to $15.1 in 2007. Assuming that the two
groups moved in parallel, the average copayment per 30 days of
supply for the case group in 2007 would have been
$15.3 + ($15.1 - $14.6) = $15.8 had VBBD not been imple-
mented. The average copayment of $10.1 per 30 days of supply
in 2007 represented a 36.1% reduction in copayment for the case
group because of the VBBD program.
Table 3 presents the mix of diabetes medications before and
after VBBD. The percentage in the table represents the total days
of diabetes medications for a particular class divided by total
days of diabetes medications. For the case group after VBBD,
there was a 3.3 percentage point increase in insulin and 1.3
percentage point increase in thiazolidinediones, two classes of
diabetes medications dominated by brand name medications. In
comparison, there was a 2.6 percentage point increase in insulin
and 0.6 percentage point decrease in thiazolidinediones for the
control group after VBBD. These data suggests that patents in the
case group shifted somewhat toward brand name medications
after VBBD, but the magnitude of change was moderate. VBBD
did not lead to a substantial change in the mix of diabetes
medications.
Table 1 Descriptive statistics
Patient baseline characteristics
Unweighted Weighted
Case:
N = 71
Control:
N = 639
t-test
P-value
Weighted
case*
Weighted
control†
t-test
P-value
Mean Age (SD) 51.1 (11.3) 58.2 (12.5) <0.001 56.2 (33.2) 57.5 (13.2) 0.13
Female (%) 57.7 47.4 0.10 45.4 48.3 0.43
Mean propensity score (SD) 0.18 (0.14) 0.09 (0.08) <0.001 0.11 (0.28) 0.10 (0.09) 0.25
Insulin use in 2005 = yes (%) 40.8 27.7 0.02 32.5 28.9 0.30
RxRisk 5: anxiety and tension (%) 16.9 14.4 0.57 14.6 14.6 0.99
RxRisk 12: coronary/peripheral vascular diseases (%) 1.4 11.1 0.01 4.1 10.2 <0.001
RxRisk 13: cystic ﬁbrosis (%) 5.6 10.6 0.19 5.8 10.1 0.03
RxRisk 14: depression (%) 35.2 25.7 0.08 24.4 26.4 0.55
RxRisk 19: gastric acid disorder (%) 19.7 25.4 0.30 29.5 24.9 0.17
RxRisk 23: heart disease/hypertension (%) 21.1 43.8 <0.001 37.3 41.6 0.24
RxRisk 26: hyperlipidemia (%) 60.6 67.4 0.24 68.0 66.7 0.72
RxRisk 27: hypertension (%) 67.6 71.4 0.51 71.7 71.0 0.84
RxRisk 30: irritable bowel syndrome (%) 11.3 10.8 0.90 10.2 10.8 0.78
RxRisk 46: thyroid disorder (%) 12.7 12.7 1.00 11.7 12.7 0.70
Data in parentheses are standard deviation (SD).
*The sum of weights for the case group was 666.9.
†The sum of weights for the control group was 708.9.
Table 2 Adherence and copayment before and after VBBD
Copayment and adherence
Unweighted Weighted
Case:
N = 71
Control:
N = 639
t-test
P-value
Weighted
case*
Weighted
control†
t-test
P-value
Average copayment of diabetes medications in 2006 (SD) 22.4 (14.8) 16.7 (10.2) <0.001 17.5 (32.0) 17.2 (11.1) 0.71
Average days of supply for diabetes medications in 2006 (SD) 39.5 (19.2) 36.9 (17.8) 0.26 36.4 (51.7) 37.2 (19.1) 0.54
Average copayment per 30 days of diabetes medications in 2006 (SD) 18.8 (14.5) 14.3 (8.0) <0.001 15.3 (28.5) 14.6 (8.8) 0.32
Average PDC in 2006 (SD) 0.86 (0.22) 0.88 (0.21) 0.37 0.88 (0.63) 0.88 (0.22) 0.87
PDC 0.8 in 2006 (%) 69.0 79.3 0.05 75.3 79.1 0.23
Average copayment of diabetes medications in 2007 (SD) 16.0 (9.7) 19.1 (13.0) 0.05 14.7 (27.6) 19.7 (14.3) <0.001
Average days of supply for diabetes medications in 2007 (SD) 46.7 (25.0) 41.6 (22.3) 0.07 44.4 (74.4) 41.9 (23.8) 0.17
Average copayment per 30 days of diabetes medications in 2007 (SD) 10.4 (3.5) 18.8 (14.5) <0.001 10.1 (10.3) 15.1 (10.0) <0.001
Average PDC in 2007 (SD) 0.89 (0.22) 0.88 (0.22) 0.84 0.90 (0.74) 0.88 (0.22) 0.33
PDC 0.8 in 2007 (%) 78.9 78.9 1.00 82.5 78.5 0.17
*The sum of propensity score weights for the case group was 666.9. †The sum of propensity score weights for the control group was 708.9.
PDC, proportion of days covered;VBBD, value-based beneﬁt design.
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VBBD Impact on Adherence
A propensity score-weighted logistic model was used to estimate
the impacts of VBBD on adherence based on the 710 patients in
the case and in the sample control group. The outcome variable
was a dichotomous variable indicating whether the patients had
PDC  0.8. Each patient had two observations, one in 2006
(before VBBD) and the other in 2007 (after VBBD). The ﬁnal
data set contained 1420 observations.
Table 4 presents the ﬁndings. Many covariates had signiﬁcant
impacts on adherence. Among them, the age coefﬁcient was
positive and signiﬁcant (0.174, P < 0.001), while the age square
variable was negative and signiﬁcant (–0.001, P < 0.001). This
suggests that the relationship between age and adherence was
indeed a curve relationship: adherence initially increased as age
increased but decreased after a certain point. When the func-
tional form of age is not correctly speciﬁed, a simple DID method
to study two groups of patients with substantially different ages
may capture the heterogeneous progression in the age/adherence
curve instead of the true treatment effect.
The regression results show that VBBD had a positive and
signiﬁcant impact on adherence. The odds ratio (OR) for VBBD
effect was 1.56 with P = 0.03, 95% conﬁdence interval (CI)
1.04–2.34. This result predicted that VBBD would increase the
percentage of adherent patients in the case group from 75.3% to
82.6%. The predicted 82.6% adherence rate was very close to
the actual adherence rate weighted by propensity score weights
(82.5%) for the case group. The increase from 75.3% to 82.6%
represented a 30.0% reduction in the number of nonadherent
patients.
A number of comorbidities, including RxRisk 12 (coronary/
peripheral vascular diseases), RxRisk 14 (depression), RxRisk 23
(heart disease/hypertension), RxRisk 26 (hyperlipidemia), and
RxRisk 27 (hypertension), were also signiﬁcant in predicting
adherence. Among them, RxRisk 12 is of particular concern
because the patients in the two groups had unbalanced RxRisk
12 even after propensity score weighting (a difference of six
percentage points, Table 1). This raises the possibility that the
estimated VBBD effect in Table 4 may be inﬂuenced by the unbal-
ance of RxRisk 12. This research performed a robustness check
by removing the patients with RxRisk 12 = 1 in the baseline
period from the analysis. After the removal of these patients, the
estimated VBBD effect became slightly stronger with OR 1.64,
95% CI 1.07–2.53, P = 0.02. This suggests that the impact of
Table 3 Mix of diabetes medications before and after VBBD
Class of diabetes
medications
Case Control
Before
VBBD (%)
After
VBBD (%)
Before
VBBD (%)
After
VBBD (%)
Sulfonylurea 30.1 27.9 26.5 26.5
Thiazolidinediones 5.7 7.0 9.8 9.2
Metformin 37.5 35.3 36.8 34.0
DPP-4 inhibitor 0.0 0.0 0.2 0.6
Combination drugs 0.7 0.1 3.8 4.0
Incretin mimetic 1.2 1.4 1.0 1.3
Insulin 24.9 28.2 21.8 24.4
Total 100.0 100.0 100.0 100.0
The percentage in this table represents the total days of supply for a class of diabetes medications divided by total days of supply for diabetes medications. Data in this table were weighted
by propensity score weights.
VBBD, value-based beneﬁt design.
Table 4 Propensity Score Weighting Logistic Model: estimation of VBBD impact on probability of PDC 0.8, N = 1420
Variables Estimate P-value Odds ratio 95% Conﬁdence interval
Intercept -4.509 <0.001
Age 0.174 <0.001 1.19 1.12 1.26
Age ¥ Age -0.001 <0.001 1.00 1.00 1.00
Male (reference group)
Female -0.357 0.001 0.70 0.57 0.86
Control group (reference group)
Case group -0.363 0.01 0.70 0.53 0.92
Year 2006 (reference group)
Year 2007 -0.085 0.55 0.92 0.70 1.21
Case group ¥ year 2007:VBBD effect 0.446 0.03 1.56 1.04 2.34
Insulin use in prior year = no (reference group)
Insulin use in prior year = yes -0.172 0.12 0.84 0.68 1.05
RxRisk 5: anxiety and tension 0.184 0.25 1.20 0.88 1.64
RxRisk 12: coronary/peripheral vascular diseases -0.861 <0.001 0.42 0.29 0.61
RxRisk 13: cystic ﬁbrosis 0.022 0.91 1.02 0.71 1.47
RxRisk 14: depression -0.614 <0.001 0.54 0.43 0.68
RxRisk 19: gastric acid disorder 0.239 0.07 1.27 0.99 1.64
RxRisk 23: heart disease/hypertension -0.661 <0.001 0.52 0.41 0.65
RxRisk 26: hyperlipidemia 0.844 <0.001 2.33 1.86 2.91
RxRisk 27: hypertension 0.909 <0.001 2.48 1.96 3.13
RxRisk 30: irritable bowel syndrome -0.343 0.05 0.71 0.51 1.00
RxRisk 46: thyroid disorder -0.086 0.58 0.92 0.68 1.25
Model statistics: percent of concordance: 66.2; c statistics: 0.664; likelihood ratio test: P < 0.0001.
PDC, proportion of days covered;VBBD, value-based beneﬁt design.
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unbalanced RxRisk 12 was likely to be small for the estimated
VBBD effect in Table 4.
To facilitate the comparison of this study with the study of
Chernew et al. [10], this research also conducted regression
analysis to analyze the change of PDC value after VBBD. Pro-
pensity score weighted regression analysis showed that VBBD led
to a statistically insigniﬁcant increase of 1.2 percentage points in
PDC (95% CI -1.2–3.6, P = 0.33). When the model was not
weighted, the VBBD effect was 2.2 percentage points on PDC
value (95% CI -2.1–6.6, P = 0.31), also insigniﬁcant. The reason
for the relatively small change in PDC value was because the
diabetes patients in the study had a high baseline PDC value
(0.88 for both the weighted case and weighted control group)
and a large number of patients had PDC = 1. For patients with
PDC = 1 or close to 1, there was little room for them to improve
PDC because the maximum PDC value was 1.
Conclusion
The issue of adherence to diabetes medication has been recog-
nized as a critical challenge in the management of diabetes. The
lack of adherence has serious long-term health and economic
consequences [3,15–23]. As the prevalence of diabetes is
expected to grow substantially in the next four decades [32], it is
important to develop effective measures to address the adherence
challenge and to improve the quality of diabetes care.
VBBD provides a new strategy for addressing the challenge of
diabetes care and managing the balance between cost and quality.
It has attracted much interest despite the paucity of supporting
data. This research provides fresh evidence on the effectiveness of
VBBD on adherence to diabetes medications. By using a propen-
sity score weighted DID method, this research provide a rigorous
assessment of the VBBD program impact.
This research found that VBBD reduced patient copayment
by 36.1% and the number of nonadherent patients by 30.0%.
The magnitude of improvement in adherence was much lower
than the reduction in the Pitney Bowes study, which showed a
two-thirds reduction in nonadherent patients. Part of the differ-
ence could be explained by the degree of copayment reduction. In
the Pitney Bowes study, the average copayment decreased by
50%. One reason for the large reduction was that Pitney Bowes
moved many drugs originally covered in tier 3 to tier 1 and thus
many patients had copayment reduction of approximately 80%
[7,33]. In contrast, although HAI offered comprehensive copay-
ment reduction for diabetes medications, many branded medica-
tions included in the VBBD were moved to from tier 2 to tier 1,
with only a few moved from tier 3 to tier 1. For this reason, the
magnitude of copayment reduction was not as dramatic.
Nevertheless, even after adjustment for degree of copayment
reduction, the difference between the two studies remained. Our
research found that a 36.1% reduction in copayment led to a
30.0% reduction in nonadherent patients, implying each percent-
age point reduction in copayment led to 0.83 percentage point
reduction in nonadherent patients. The Pitney Bowes study
found that each percentage point reduction was associated with
1.32 percentage point reduction in nonadherent patients, 58%
higher than the rate of reduction in this study. One reason to
explain the discrepancy is that Pitney Bowes rolled out disease
management program along with the VBBD. The difference may
reﬂect the effect of the disease management program.
The effect observed in this research was likely to be in the
range observed at the Chernew et al. study. The MPR measure in
the Chernew et al. study was deﬁned as number of days patients
possessed medications divided by total number of days, similar to
the PDC measure in this research. For this reason, a rough
comparison can be made between PDC in our study and MPR in
the Chernew et al. study. Our research observed that VBBD led
to a statistically insigniﬁcant increase of PDC by 1.2 percentage
point, lower than the 4.02 percentage point increase in MPR
observed in the Chernew et al. study. Multiple reasons could
contribute to the difference between the two studies. First, dif-
ference in methodology might play a role. Without propensity
score weighting, the change of PDC would have been 2.2 per-
centage points, closer to the ﬁndings in the Chernew et al. study.
Second, the patients in our study had a much higher baseline
adherence level. The baseline PDC was 0.88 for the case group
(Table 2) in comparison to a baseline MPR of 0.69 in the
Chernew et al. study. It could be harder to improve adherence
percentage points with a high baseline adherence rate. In terms of
take-up percentage, deﬁned as change in MPR divided by (1 -
baseline MPR) in the Chernew et al. study, this research found a
10.0 take-up percentage when propensity score weighting was
used and 18.3 take-up percentage when propensity score weight-
ing was not used, not far from the 13.2 take-up percentage
observed in the Chernew et al. study. Finally, our research had a
relatively small sample size of 710 patients while there were more
than 4500 patients in Chernew et al.’s study. It was easier to ﬁnd
statistically signiﬁcant results in the Chernew et al. study because
of the large sample size.
This research is limited in several areas. First, only pharmacy
data were used to study the impact of VBBD. Though adherence
is a proven intermediate variable in measuring quality of care,
more deﬁnitive proof of the impact of VBBD on quality of care
needs to come from clinical measures, such as HbA1c values and
diabetes-related hospitalizations. Second, the adherence measure
PDC used in this research measures adherence to all diabetes
medications but may not reveal the differences of adherence to
subclasses of diabetes medications. Third, only short-term data
were analyzed, and the long-term impact of VBBD on medication
adherence remains unknown. Fourth, the case group represented
a relatively small sample of HAI diabetics, which makes it difﬁ-
cult to generalize the results. In addition, the improvement in
adherence associated with a $5 reduction in copayment may not
necessarily be applicable in other parts of the country because
price sensitivity may vary. Finally, VBBD may inﬂuence the use of
diabetes medications in addition to adherence. For example,
clinical inertia has been recognized as an important problem in
the treatment of diabetes as patients are reluctant to augment
their diabetes medications [34]. The results in Table 3 indicate
that there was a small shift toward brand medications after the
implementation of VBBD. A VBBD research with more observa-
tions and a longer time frame is needed to investigate whether
VBBD helps patients overcome clinical inertia and augment
medications more timely.
Despite these limitations, our research found that VBBD sig-
niﬁcantly reduced the proportion of nonadherent diabetes
patients. This ﬁnding supports more experiments with VBBD.
More research is needed on VBBD to help reduce barriers to
medications for patients with chronic illnesses.
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